Biren Amin
Stock Analyst at Piper Sandler
(3.20)
# 1,083
Out of 5,127 analysts
66
Total ratings
50.85%
Success rate
2.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Overweight | $7 | $2.00 | +250.00% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $27.89 | +72.10% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $23.15 | -30.89% | 12 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $93 → $98 | $73.82 | +32.76% | 4 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $15.24 | +339.63% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $11.38 | +172.41% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $63.40 | +49.84% | 2 | Sep 25, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $2.68 | +123.88% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $1.60 | +150.00% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $5.31 | +220.15% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $1.49 | +369.80% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $22.05 | +72.34% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.17 | +132.11% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $31.65 | +124.33% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.36 | +318.66% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $20.45 | +2.69% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $64.31 | +78.82% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $26.26 | +21.86% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.75 | -20.00% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $2.84 | +2,364.79% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.40 | +12,630.90% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $4.18 | +474.16% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $5.14 | +561.48% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.65 | +76,941.60% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.32 | +50.21% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $801.01 | -13.73% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $4.26 | +134.74% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $43.80 | +130.59% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $135.57 | -49.10% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $469.68 | -67.00% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $4.70 | +2,793.62% | 4 | Mar 6, 2017 |
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $2.00
Upside: +250.00%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $27.89
Upside: +72.10%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $23.15
Upside: -30.89%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $73.82
Upside: +32.76%
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $15.24
Upside: +339.63%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $11.38
Upside: +172.41%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $63.40
Upside: +49.84%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $2.68
Upside: +123.88%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $1.60
Upside: +150.00%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $5.31
Upside: +220.15%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.49
Upside: +369.80%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $22.05
Upside: +72.34%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $5.17
Upside: +132.11%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $31.65
Upside: +124.33%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $8.36
Upside: +318.66%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $20.45
Upside: +2.69%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $64.31
Upside: +78.82%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $26.26
Upside: +21.86%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.75
Upside: -20.00%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $2.84
Upside: +2,364.79%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.40
Upside: +12,630.90%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $4.18
Upside: +474.16%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $5.14
Upside: +561.48%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.65
Upside: +76,941.60%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $9.32
Upside: +50.21%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $801.01
Upside: -13.73%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $4.26
Upside: +134.74%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $43.80
Upside: +130.59%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $135.57
Upside: -49.10%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $469.68
Upside: -67.00%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $4.70
Upside: +2,793.62%